Join GATC Health for a virtual key opinion leader (KOL) event featuring Lin Yu, PhD (Former Managing Director, Oppenheimer Healthcare Investment Banking), Tomas Philipson, PhD (Former Acting Chairman, Council of Economic Advisers, Executive Office of the President), and Greg Sarafin (Former Global Vice Chair, Ernst & Young), who will join members of company management Rahul Gupta, MD, MPH, MBA, FACP (Former Director, National Drug Control Policy; President, GATC Health) and Tyrone Lam (Chief Business Officer, GATC Health), to discuss Derisq™, the standard AI report for predictive risk intelligence.

The Derisq AI Report uses GATC Health’s proprietary AI platform to provide biopharma leaders and investors with an objective, data-driven assessment of a drug candidate’s likely endpoint performance—streamlining pipeline prioritization, optimizing trial design, and revealing risks that traditional approaches may overlook. It delivers validated, actionable insights on drug safety, efficacy, and off-target risks, revolutionizing how the industry evaluates therapeutic potential. This underlying technology has been independently verified by University of California Irvine, demonstrating 91% specificity and 86% sensitivity.

KOLs and members of company management will provide an overview of Derisq’s elevated strategic planning, and how it empowers biotech leaders and investors to make informed decisions with confidence long before committing to clinical trials.

A live question and answer session will follow the formal presentations.